Latest Breaking News On - Christina tartaglia - Page 5 : comparemela.com

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary.

United statesMacau generalHong kongCarl regilloJay dukerChristina tartagliaCharlesc wykoffAmy phillipsGlobenewswire incEyepoint pharmaceuticals nasdaqThomas jefferson universityEyepoint pharmaceuticals incExchange commissionEquinox sciencesEyepoint pharmaceuticalsGreen room communications

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongMacau generalCarl regilloJay dukerCharlesc wykoffChristina tartagliaAmy phillipsGreen room communicationsExchange commissionEyepoint pharmaceuticalsThomas jefferson universityDrug administrationEquinox sciencesEyepoint pharmaceuticals nasdaqEyepoint pharmaceuticals inc

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesChristina tartagliaStern investor relations incFate therapeutics incCompensation committeeRestated inducement equity planNasdaq listing ruleFate therapeuticFate therapeuticsInvestor relations

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 02, 2024 Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell -derived cellular.

San diegoUnited statesChristina tartagliaFate therapeutics incStern investor relations incCompensation committeeRestated inducement equity planNasdaq listing ruleFate therapeuticFate therapeuticsInvestor relations

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)

WATERTOWN - EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that.

Macau generalUnited statesHong kongChristina tartagliaAmy phillipsCompensation committeeEyepoint pharmaceuticalsEyepoint pharmaceuticals nasdaqEyepoint pharmaceuticals incEquinox sciencesPoint pharmaceuticalsTerm incentive planPoint pharmaceuticalNews publishing